Abstract: A method of manufacturing a hydraulic shock absorber is provided with a piston main body manufacturing step 21 including the process of sintering of the piston main body and the process of forming of the molded sealing are performed, a piston assembly manufacturing step 22 including process of forming of the throttle oil passage on the piston main body manufactured in the piston main body manufacturing step 21 and the assembly of valves onto the piston main body, and a hydraulic shock absorber manufacturing step 23 for manufacturing a hydraulic shock absorber using the piston assembly. In this manner, it is not necessary to provide for an intermediate inventory between each process. Furthermore inventory monitoring processes are simplified in the piston main body manufacturing step and productivity is increased since it is not necessary to monitor the inventory level with respect to a plurality of piston assembly types with different valves or throttle hydraulic passages.

Abstract: A method of manufacturing a hydraulic shock absorber is provided with a piston main body manufacturing step 21 including the process of sintering of the piston main body and the process of forming of the molded sealing are performed, a piston assembly manufacturing step 22 including process of forming of the throttle oil passage on the piston main body manufactured in the piston main body manufacturing step 21 and the assembly of valves onto the piston main body, and a hydraulic shock absorber manufacturing step 23 for manufacturing a hydraulic shock absorber using the piston assembly. In this manner, it is not necessary to provide for an intermediate inventory between each process. Furthermore inventory monitoring processes are simplified in the piston main body manufacturing step and productivity is increased since it is not necessary to monitor the inventory level with respect to a plurality of piston assembly types with different valves or throttle hydraulic passages.

Abstract: There is provided a cephalosporin derivative represented by the general formula (1): ##STR1## wherein R.sup.101, R.sup.102, R.sup.103 and Y.sup.101 are as difined; the general formula (2): ##STR2## wherein R.sup.201, R.sup.202 and R.sup.203 are as defined above; the general formula (3): ##STR3## wherein R.sup.301, R.sup.302, Y.sup.301, Y.sup.302 and A.sup.301 are as defined; or pharmaceutically acceptable salt thereof. The compound is useful as an active ingredient of antimicrobial agent.

Abstract: A 2-oxa-isocephem compound of the formula (1): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined, pharmaceutically acceptable salts thereof, composition containing the same and processes for preparing the same are disclosed. The compound is useful as an antimicrobial agent.

Abstract: There is described a 2-oxa-isocephem compound of the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.4 are as defined, and R.sup.3 is a group of the formula: ##STR2## wherein n, m, R.sup.6, R.sup.7, B.sup.- and l are as defined, or pharmaceutically acceptable salt thereof. The compound has antimicrobial activity.

Abstract: A 2-oxa-isocephem compound of the formula (1): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined, pharmaceutically acceptable salts thereof, composition containing the same and processes for preparing the same are disclosed. The compound is useful as an antimicrobial agent.

Abstract: A 2-oxa-isocephem compound of the formula (1): ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined, pharmaceutically acceptable salts thereof, esters of the carboxy group in the 4-position thereof and quaternary ammonium salts thereof, composition containing the same and processes for preparing the same are disclosed. The compound is useful as an antimicrobial compound.

Abstract: Amidine compounds of formula (I) ##STR1## and the pharmaceutically acceptable acid addition salts thereof are novel and are of use as anti-trypsin, anti-plasmin, anti-kallikrein, anti-thrombin and anti-complement agents which may be administered orally. These amidine compounds can be produced by the reaction between a carboxylic acid compound of formula (II) ##STR2## or a reactive intermediate thereof and 6-amidino-2-naphthol of formula (III) ##STR3## or preferably an acid addition salt thereof.

Abstract: Amidine compounds of formula (I) ##STR1## and the pharmaceutically acceptable acid addition salts thereof are novel and are of use as anti-trypsin, anti-plasmin, anti-kallikrein, anti-thrombin and anti-complement agents which may be administered orally. These amidine compounds can be produced by the reaction between a carboxylic acid compound of formula (II) ##STR2## or a reactive intermediate thereof and 6-amidino-2-naphthol of formula (III) ##STR3## or preferably an acid addition salt thereof.

Abstract: Amidine compounds of the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful anti-trypsin, anti-plasmin, anti-kallikrein and anti-thrombin agents. They are also useful as a powerful anti-complement agent.

Abstract: Amidine compounds of the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful anti-trypsin, anti-plasmin, anti-kallikrein and anti-thrombin agents. They are also useful as a powerful anti-complement agent.